Cytune Pharma

Restoring immune system

Project Description

Develops a “best-in-class” cytokine to stimulate immune T and NK cells (channel IL-2 / IL-15)

The flagship product RLI-15 shows, in preclinical models, a therapeutic window well above that of IL-2, the only drug approved in this segment

Exit achieved in 2015 Q1 with PPF/Sotio group

David BECHARD
Founder & CEO

Serial entrepreneur. 10 years of experience in the biotech; Expert in immuno-oncology

Active international network in the areas of venture capital, business development (pharma / biotech), the regulatory development, innovative clinical and scientific development of private and public entities

Project Details

Back to Top